Last reviewed · How we verify
NCT06647771
Relationship Between Postoperative Tempeartive and Acute Kidney Injury
trial in Patients Undergoing Valvular Heart Surgery in 3,274 participants. Participants enrolled and being followed up; not accepting new ones.
11 August 2026
Quick facts
| Lead sponsor | Yonsei University |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 3,274 |
| Start date | 12 August 2024 |
| Primary completion | 11 August 2026 |
| Estimated completion | 11 August 2026 |
| Sites | 1 location across South Korea |
Conditions studied
- Patients Undergoing Valvular Heart Surgery — all drugs for Patients Undergoing Valvular Heart Surgery →
Sponsor
Yonsei University
Who can join
18 and older, any sex, with Patients Undergoing Valvular Heart Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators aimed to identify body temperature trajectory classes based on core temperature changes during the first 12 hours post-surgery and to explore their relationship with postoperative acute kidney injury in patients undergoing valvular heart surgery.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Association Between Early Postoperative Temperature Trajectories and Severe Acute Kidney Injury After Valvular Heart Surgery: A Retrospective Cohort Study
Cho J, Suh S, Shim J, Lee H, et al · · 2026
Verify or expand the search:
- PubMed search for NCT06647771
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Patients Undergoing Valvular Heart Surgery
Currently open trials in the same condition.
- NCT06647758 — Association Between Post-operative Anemia and Mortality After Valvular Heart Surgery · active not recruiting
Other Yonsei University trials
Trials by the same sponsor.
- NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
- NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
- NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
- NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
- NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06647771 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yonsei University
- Last refreshed: 18 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06647771.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing